Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient
- PMID: 31397040
- DOI: 10.1002/pbc.27956
Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient
References
REFERENCES
-
- Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283-299.
-
- Tamamyan G, Danielyan S, Lambert MP. Chemotherapy induced thrombocytopenia in pediatric oncology. Crit Rev Oncol Hematol. 2016;99:299-307.
-
- Escudero Vilaplana V, Aragonés JH, Fernández-Llamazares CM, Bieler CB, Rodríguez SM, Sáez MS. Use of romiplostim for primary immune thrombocytopenia in children. Pediatr Hematol Oncol. 2012;29(2):197-205.
-
- Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217-1222.
-
- Arora N, Gupta A, Li HC, Sadeghi N. Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness. BMJ Case Rep. 2018;11(1). https://doi.org/10.1136/bcr-2018-226497.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources